Publications

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Authors: RC Coombes, PD Badman, JP Lozano-Kuehne, X Liu, IR Macpherson, I Zubairi, R...

E-pub date: 17 Jan 2023

Journal name: Nat Commun

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.

Authors: A Weir, E-Y Kang, NS Meagher, GS Nelson, P Ghatage, C-H Lee, MJ Riggan, A G...

E-pub date: 1 Jan 2023

Journal name: Br J Cancer

Profiling the immune landscape in mucinous ovarian carcinoma.

Authors: NS Meagher, P Hamilton, K Milne, S Thornton, B Harris, A Weir, J Alsop, C B...

E-pub date: 1 Jan 2023

Journal name: Gynecol Oncol

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.

Authors: MT Phung, PM Webb, A DeFazio, S Fereday, AW Lee, DDL Bowtell, PA Fasching, ...

E-pub date: 1 Jan 2023

Journal name: Gynecol Oncol

Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.

Authors: I-G Funingana, JS Bedia, Y-W Huang, A Delgado Gonzalez, K Donoso, VD Gonzal...

E-pub date: 1 Jan 2023

Journal name: Semin Immunopathol

Resolution enhanced imaging for endoscopy using diffractive optics

Authors: N Xu, C Williams, G Spicer, SE Bohndiek, Q Tan

E-pub date: 1 Jan 2023

Journal name: Proceedings of SPIE - The International Society for Optical Engineering

DNA G-Quadruplex Recognition In Vitro and in Live Cells by a Structure-Specific Nanobody.

Authors: S Galli, L Melidis, SM Flynn, D Varshney, A Simeone, J Spiegel, SK Madden, ...

E-pub date: 21 Dec 2022

Journal name: J Am Chem Soc

Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies.

Authors: SA Wild, IG Cannell, A Nicholls, K Kania, D Bressan, CRUK IMAXT Grand Chal...

E-pub date: 16 Dec 2022

Journal name: Elife

Filters

Research Groups

Core Facilities

Start date

End date

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.

Profiling the immune landscape in mucinous ovarian carcinoma.

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.

Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.

Resolution enhanced imaging for endoscopy using diffractive optics

DNA G-Quadruplex Recognition In Vitro and in Live Cells by a Structure-Specific Nanobody.

Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.

Profiling the immune landscape in mucinous ovarian carcinoma.

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.

Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.

Resolution enhanced imaging for endoscopy using diffractive optics

DNA G-Quadruplex Recognition In Vitro and in Live Cells by a Structure-Specific Nanobody.

Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies.